LAS 35201

Drug Profile

LAS 35201

Alternative Names: LAS-35201

Latest Information Update: 23 Aug 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Almirall-Prodesfarma
  • Developer Almirall S.A.
  • Class Antibronchitics
  • Mechanism of Action Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 11 Sep 2005 Phase-II clinical trials in Asthma in Europe (unspecified route)
  • 11 Sep 2005 Phase-II clinical trials in Bronchitis in Europe (unspecified route)
  • 11 Sep 2005 Phase-II clinical trials in Chronic obstructive pulmonary disease in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top